ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      AI Subscribe Login/Register Profile Icon
      S&P 500
      5,704.23
      -0.16%
      US Tech 100
      19,281.60
      -0.27%
      Dow Jones
      42,087.60
      0.15%
      Brent Oil
      74.325
      0.01%
      Bitcoin
      62,931.76
      -0.03%
      Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ

      6. Merus NV (MRUS) Quote

      Merus NV

      Merus NV (MRUS)

      NASDAQ
      49.695
      -1.12
      ( -2.19% )
      Updated: 12:28:43
      Delayed by 15 minutes

      Empower your portfolio: Real-time discussions and actionable trading ideas.

      Premium

      Key stats and details

      Current Price
      49.695
      Bid
      49.63
      Ask
      49.80
      Volume
      263,348
      49.67 Day's Range 51.275
      19.805 52 Week Range 61.61
      Market Cap
      3.39B
      Previous Close
      50.81
      Open
      50.73
      Last Trade
      2
      @
      49.695
      Last Trade Time
      12:29:25
      Financial Volume
      $ 13,276,381
      VWAP
      50.4138
      Average Volume (3m)
      589,800
      Shares Outstanding
      68,210,479
      Dividend Yield
      -
      PE Ratio
      0.00
      Earnings Per Share (EPS)
      -
      Revenue
      43.95M
      Net Profit
      -154.94M

      About Merus NV

      Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing innovative full-length human bispecific antibody therapeutics, referred to as Biclonics. Merus only reportable segment comprising the discovery and development of innovative ... Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing innovative full-length human bispecific antibody therapeutics, referred to as Biclonics. Merus only reportable segment comprising the discovery and development of innovative bispecific therapeutics. Some of its products in the pipeline include MCLA-128; MCLA-117; MCLA-158 and others. Show more

      Sector
      Gen Med & Surgical Hospitals
      Industry
      Gen Med & Surgical Hospitals
      Website
      www.merus.nl
      Headquarters
      Utrecht, Utrecht, Nld
      Founded
      -
      Merus NV is listed in the Gen Med & Surgical Hospitals sector of the NASDAQ with ticker MRUS. The last closing price for Merus NV was $50.81. Over the last year, Merus NV shares have traded in a share price range of $ 19.805 to $ 61.61.

      Merus NV currently has 68,210,479 shares outstanding. The market capitalization of Merus NV is $3.47 billion.

      Ask ADVFN Intelligence (AI)

      MRUS Latest News

      More News

      Merus Announces Abstract Accepted for Presentation at the ESMO Asia Congress 2024

      UTRECHT, The Netherlands and CAMBRIDGE, Mass., Sept. 17, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing...

      September 17 2024
      GlobeNewswire Inc.

      Form 4 - Statement of changes in beneficial ownership of securities

      August 22 2024
      Edgar (US Regulatory)

      Merus to Present at Canaccord Genuity’s 44th Annual Growth Conference

      UTRECHT, The Netherlands and CAMBRIDGE, Mass., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific...

      August 06 2024
      GlobeNewswire Inc.

      Merus Announces Financial Results for the Second Quarter 2024 and Provides Business Update

      – Petosemtamab in combination with pembrolizumab interim data presented at 2024 ASCO® demonstrated robust 67% response rate among 24 evaluable patients – First patients dosed in phase 3 trial...

      August 01 2024
      GlobeNewswire Inc.

      Form 10-Q - Quarterly report [Sections 13 or 15(d)]

      August 01 2024
      Edgar (US Regulatory)

      Merus Announces First Patient Dosed in LiGeR-HN2, a Phase 3 Trial Evaluating Petosemtamab in 2/3L r/m HNSCC

      UTRECHT, The Netherlands and CAMBRIDGE, Mass., July 24, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing...

      July 24 2024
      GlobeNewswire Inc.

      Merus Announces First Patient Dosed in Phase 2 Trial of Petosemtamab in 2L CRC

      UTRECHT, The Netherlands and CAMBRIDGE, Mass., July 08, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing...

      July 08 2024
      GlobeNewswire Inc.

      Merus Appoints Fabian Zohren M.D., Ph.D., as Chief Medical Officer

      UTRECHT, The Netherlands and CAMBRIDGE, Mass., July 01, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing...

      July 01 2024
      GlobeNewswire Inc.

      Form 144 - Report of proposed sale of securities

      June 17 2024
      Edgar (US Regulatory)

      Form 4 - Statement of changes in beneficial ownership of securities

      June 12 2024
      Edgar (US Regulatory)
      PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
      10.3250.65829451083749.3751.3448.7862728650.25607634CS
      4-3.805-7.1121495327153.554.62548.1249216550.63602329CS
      12-10.255-17.105921601359.9561.2847.500158980053.32273456CS
      265.04511.298992161344.6561.6139.2777501551.56850908CS
      5224.64598.383233532925.0561.6119.80563882844.14874666CS
      15624.53597.515898251225.1661.6112.0342990733.34277663CS
      26030.495158.82812519.261.6110.1831102930.73155612CS

      Movers

      View all
      • Most Active
      • % Gainers
      • % Losers
      SymbolPriceVol.
      XPONExpion360 Inc
      $ 0.126
      (116.49%)
      		1.24B
      GXAIGaxos ai Inc
      $ 4.1799
      (78.63%)
      		24.52M
      BNZIBanzai International Inc
      $ 5.0908
      (76.76%)
      		53.65M
      LFLYLeafly Holdings Inc
      $ 2.58
      (44.13%)
      		26.59M
      IMRXImmuneering Corporation
      $ 3.2099
      (32.64%)
      		11.09M
      GSIWGarden Stage Ltd
      $ 2.56
      (-67.31%)
      		9.42M
      CRBPCorbus Pharmaceuticals Holdings Inc
      $ 20.625
      (-60.11%)
      		8.75M
      LGCBLinkage Global Inc
      $ 0.4109
      (-58.44%)
      		1.59M
      SKYESkye Bioscience Inc
      $ 3.20
      (-41.71%)
      		2.77M
      KOPNKopin Corporation
      $ 0.6412
      (-33.49%)
      		8.03M
      XPONExpion360 Inc
      $ 0.126
      (116.49%)
      		1.24B
      NVDANVIDIA Corporation
      $ 116.7401
      (-0.96%)
      		147.76M
      VERBVerb Technology Company Inc
      $ 0.066499
      (19.60%)
      		140.33M
      SQQQProShares UltraPro Short QQQ
      $ 7.8401
      (1.03%)
      		91.68M
      HOLOMicroCloud Hologram Inc
      $ 0.2436
      (5.18%)
      		67.6M

      MRUS Discussion

      View Posts
      Monksdream Monksdream 6 days ago
      MRUS range bound
      👍️0
      Phosphene Phosphene 4 years ago
      Merus and myTomorrows Announce Expansion of Collaboration for Screening and eNRGy Clinical Trial Awareness for Cancer Patients with Neuregulin 1 Fusion Tumors

      https://www.globenewswire.com/news-release/2020/10/12/2107078/0/en/Merus-and-myTomorrows-Announce-Expansion-of-Collaboration-for-Screening-and-eNRGy-Clinical-Trial-Awareness-for-Cancer-Patients-with-Neuregulin-1-Fusion-Tumors.html
      👍️0
      Phosphene Phosphene 4 years ago
      The Baker Brothers have 7% ownership.

      https://whalewisdom.com/filer/baker-bros-advisors-llc#tabholdings_tab_link
      👍️0
      Phosphene Phosphene 4 years ago
      Board Member: Victor Sandor

      https://ir.merus.nl/board-member/victor-sandor

      https://www.businesswire.com/news/home/20200824005127/en/Prelude-Therapeutics-Announces-Closing-50M-Series-Financing
      👍️0
      Phosphene Phosphene 4 years ago
      Second Quarter 2020 Results:

      https://www.globenewswire.com/news-release/2020/08/06/2074649/0/en/Merus-Announces-Financial-Results-for-the-Second-Quarter-and-Provides-Business-Update.html
      👍️0
      Phosphene Phosphene 4 years ago
      https://merus.nl/
      👍️0
      Phosphene Phosphene 4 years ago
      European cancer biotech Merus nabs Sanofi I-O chief Andrew Joe

      https://www.fiercebiotech.com/biotech/european-cancer-biotech-merus-nabs-sanofi-i-o-chief-andrew-joe
      👍️0

      Your Recent History

      NASDAQ
      MRUS
      Merus NV
      Delayed Upgrade Clock